Thomas Tuschl is a professor of molecular biology at Rockefeller University, and an investigator with the Howard Hughes Medical Institute.

Dr. Tuschl is investigating different gene regulatory mechanisms that are triggered by double-stranded RNA and RNA-binding proteins in mostly human cells, with the goal of developing a new generation of therapeutic treatments for genetic diseases.

Dr. Tuschl molecularly characterized small interfering RNAs, a class of double-stranded molecules 21 nucleotides long that guide sequence-specific gene silencing, and was the first to demonstrate their utility in knocking down human gene expression.

Dr. Tuschl received his Ph.D. in chemistry from the University of Regensburg, in Germany, in 1995. He went to the Max Planck Institute for Experimental Medicine in Göttingen, Germany, pursuing research with Fritz Eckstein. He next joined the biology department at the Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research, where he worked with Phillip A. Sharp and David P. Bartel. Dr. Tuschl was a junior investigator at the Max Planck Institute for Biophysical Chemistry before coming to Rockefeller in 2003 as associate professor. He was named professor in 2009.

Dr. Tuschl is a member of the German National Academy of Sciences Leopoldina, and his most recent honors include the Ernst Jung Prize for Medicine in 2008 and the Max Delbrück Medal and the Karl Heinz Beckurtz Award in 2007. In 2006 he received the Molecular Bioanalytics Prize from Roche Diagnostics. In 2005 he was named a fellow of the New York Academy of Sciences and received the Meyenburg Prize, the Irma T. Hirschl Trust Career Scientist Award and the Ernst Schering Award. In 2003 he received the Wiley Prize in Biomedical Sciences, the New York City Mayor’s Award for Excellence in Science and Technology and the Newcomb Cleveland Prize from the American Association for the Advancement of Science. Dr. Tuschl was the recipient of the European Molecular Biology Organization Young Investigator Award in 2001. He is also a Howard Hughes Medical Institute investigator.